Vertex International Securities Ltd is targeting to raise Sh10 billion as it launches two pioneering products set to reshape Tanzania’s capital markets.The two products are the Vertex International ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

Vertex Pharmaceuticals' non-opioid painkiller significantly decreased pain in patients with diabetes suffering from chronic nerve pain in a mid-stage trial, fueling efforts to develop a treatment ...

Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors By Nick Paul Taylor Dec 19, 2024 7:41am Vertex Pharmaceuticals pain drug clinical trial data Clinical Data ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-deri ...